Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Adicet Bio (ACET) shares

Learn how to easily invest in Adicet Bio shares.

Adicet Bio is a biotechnology business based in the US. Adicet Bio stocks (ACET.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $10.97 – a decrease of 11.86% over the previous week. Adicet Bio employs 81 staff and has a trailing 12-month revenue of around $9.7 million.

How to buy shares in Adicet Bio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ACET – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Adicet Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Adicet Bio's stock price?

Since the stock market crash in March caused by coronavirus, Adicet Bio's stock price has had significant positive movement.

Its last market close was $13.15, which is 88.44% up on its pre-crash value of $1.52 and 1,429.07% up on the lowest point reached during the March crash when the stocks fell as low as $0.86.

If you had bought $1,000 worth of Adicet Bio stocks at the start of February 2020, those stocks would have been worth $692.86 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $9,392.91.

Adicet Bio stock price (NASDAQ:ACET)

Use our graph to track the performance of ACET stocks over time.

Adicet Bio shares at a glance

Information last updated 2022-01-18.
Latest market close$13.15
52-week range$6.25 - $18.49
50-day moving average $12.95
200-day moving average $10.65
Wall St. target price$30.86
PE ratio N/A
Dividend yield N/A (7.43%)
Earnings per share (TTM) $-2.01

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Adicet Bio price performance over time

Historical closes compared with the close of $13.15 from 2022-01-18

1 week (2022-01-12) -11.86%
1 month (2021-12-17) -17.03%
3 months (2021-10-19) 50.46%
6 months (2021-07-19) 63.97%
1 year (2021-01-19) -2.52%
2 years (2020-01-17) 800.68%
3 years (2019-01-18) 52.38%
5 years (2017-01-15) N/A

Is Adicet Bio under- or over-valued?

Valuing Adicet Bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adicet Bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Adicet Bio's PEG ratio

Adicet Bio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.82. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adicet Bio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Adicet Bio financials

Revenue TTM $9.7 million
Gross profit TTM $17.9 million
Return on assets TTM -14.06%
Return on equity TTM -33.01%
Profit margin 0%
Book value $6.80
Market capitalisation $569.9 million

TTM: trailing 12 months

Adicet Bio share dividends

We're not expecting Adicet Bio to pay a dividend over the next 12 months.

Have Adicet Bio's shares ever split?

Adicet Bio's shares were split on a 1:7 basis on 15 September 2020. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Adicet Bio shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Adicet Bio shares which in turn could have impacted Adicet Bio's share price.

Adicet Bio overview

Adicet Bio, Inc. , a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site